Skip to Content

NOVO Nordisk ADR (NVO US)

NVO US$38.87

20 minute delayed

Today ▼ -1.42%
1 year return ▼ -20.67%
Volume 1,901,826
Div yield 4.56%
PE ratio 10.38
52 week range
35.13 62.43

14 days free access

Join Market Matters and get full access to all our Opinion + Action

Learn more

Performance

Advanced charting functionality with the ability to amend timeframes, chart type & indicator selection, powered by TradingView.

Share price activity

Displays share price activity. Volume = number of shares traded, Turnover = value of shares traded, VWAP = volume-weighted average price for the day, sourced from Morningstar.
Last (Price)
38.87
Change
▼ -0.56 (-1.42)
Bid / Ask
38.89 - 38.90
Volume
1,901,826
Turnover
69,077,764
Open
39.40
Day Range
38.61 - 39.81
VWAP
38.94
Prev Close
39.43
Last Trade
19/11 7:00pm
Displays useful ratios for the security, NB the pricing date used, sourced from Morningstar.
Ratios
Currency (Price/reporting): USD/DKK
Exchange Rate: —
Price, volume and trading statistics for the security, sourced from Morningstar.
Price - closing or last bid 40.70
Price - 12 month high 62.43
Price - 12 month low 35.13
Pricing date 17 NOV 2026
Volume - avg. trading volume for the last ten days 14.01
Market capitalization 131,399.80
12 Month High price date 22 JAN 2026
12 Month Low price date 30 MAR 2026
Volume - avg. trading volume for the last 3 months 12.43
Price - 1 Day % Change -2.16%
Price - 13 week price percent change -9.31%
Price - 26 week price percent change -9.03%
Price - 5 Day % Change 0.00%
Price - 52 week price percent change -16.01%
Price - YTD price percent change -20.54%
Price % Change Month To Date 4.82%
Earnings, dividends, cash flow and book value per share, sourced from Morningstar.
EPS excluding extraordinary items - most recent fiscal year 23.030
EPS excluding extraordinary items - trailing 12 month 25.490
EPS Normalized - most recent fiscal year 26.170
Revenue/share - most recent fiscal year 69.489
Revenue/share - trailing 12 month 75.143
Book value per share - most recent fiscal year 43.670
Book value per share - most recent quarter 49.334
Book value (tangible) per share - most recent fiscal year 14.402
Book value (tangible) per share - most recent quarter 24.016
Cash per share - most recent fiscal year 5.956
Cash per share - most recent quarter 10.001
Cash Flow per share - most recent fiscal year 25.938
Cash Flow per share - trailing 12 month 28.564
Dividend per share - most recent fiscal year 11.700
Dividends per share - trailing 12 month 1.797
EBITD per share - trailing 12 month 37.810
EPS Basic excluding extraordinary items - most recent fiscal year 23.060
EPS Basic excluding extraordinary items - trailing 12 month 25.530
EPS including extraordinary items - most recent fiscal year 23.060
EPS including extraordinary items - trailing 12 month 25.530
Free Cash Flow per share - trailing 12 month 10.016
Valuation multiples such as P/E, price to sales, price to book and enterprise value ratios, sourced from Morningstar.
P/E excluding extraordinary items, most recent fiscal year 9.95
P/E Normalized, most recent fiscal year 9.95
Price to sales - most recent fiscal year 3.37
Price to Tangible Book - most fiscal year 10.82
Price to Free Cash Flow per Share - most recent fiscal year 25.32
Price to Cash Flow per share - trailing 12 month 8.88
Price to Book - most recent fiscal year 5.27
P/E excluding extraordinary items high, trailing 12 months 18.55
P/E excluding extraordinary items low, trailing 12 months 9.12
Net Debt, LFI 88,128.00
Net Debt, LFY 103,996.00
Dividend Yield - 5 Year Average 1.52%
Dividend Yield - indicated annual dividend divided by closing price 4.32%
Current Dividend Yield - Common Stock Primary Issue, LTM 4.56%
Cash flow, liquidity and leverage measures, sourced from Morningstar.
Free Cash Flow - most recent fiscal year 25,252.00
LT debt/equity - most recent fiscal year 61.29%
Payout ratio - most recent fiscal year 50.80%
Total debt/total equity - most recent fiscal year 67.49%
LT debt/equity - most recent quarter 54.06%
Total debt/total equity - most recent quarter 61.74%
Free Cash Flow - trailing 12 month 44,472.00
Payout ratio - trailing 12 month —
Key income statement lines for the most recent fiscal year, in millions, sourced from Morningstar.
Revenue - most recent fiscal year 309,064.00
Revenue - trailing 12 month 333,650.00
EBITD - most recent fiscal year 148,144.00
EBITD - trailing 12 month 167,884.00
Earnings before taxes - most recent fiscal year 130,540.00
Earnings before taxes - trailing 12 month 144,666.00
Net Income available to common - most recent fiscal year 102,434.00
Net Income available to common - trailing 12 months 113,177.00
Earnings before taxes Normalized - most recent fiscal year 137,785.00
Net Income Available to Common, Normalized - most recent fiscal year 116,407.00
Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding, TTM 25.49
Profitability margins for the most recent fiscal year, sourced from Morningstar.
Net Profit Margin % - 1st historical fiscal year 33.14%
Net Profit Margin % - trailing 12 month 33.92%
Operating margin - 1st historical fiscal year 41.30%
Operating margin - trailing 12 month 42.39%
Pretax margin - trailing 12 month 43.36%
Pretax margin - 1st historical fiscal year 42.24%
Operating Margin - 5 year average 42.72%
Pretax Margin - 5 year average 42.42%
Free Operating Cash Flow/Revenue, 5 Year Average 26.99%
Free Operating Cash Flow/Revenue, TTM 13.33%
Net Profit Margin - 5 year average 33.85%
Returns on average assets and equity for the fiscal year, the trailing 12 months and as 5 year averages, and net income and revenue per employee in whole currency, sourced from Morningstar.
Return on average assets - most recent fiscal year 20.55%
Return on average assets - trailing 12 month 20.15%
Return on average equity - most recent fiscal year 62.92%
Return on average equity - trailing 12 month 56.25%
Return on average assets - 5 year average 26.13%
Return on average equity - 5 year average 78.16%
Net Income/employee - most recent fiscal year 1,488,996.13
Revenue/employee - most recent fiscal year 4,492,601.10
Growth in revenue, earnings, dividends and book value over recent periods, sourced from Morningstar.
Revenue growth rate, 5 year 19.48%
EPS growth rate, 5 year 20.66%
Growth rate% - dividend, 3 year 31.56%
Revenue/share (5 yr growth) 20.70%
Growth rate% - Revenue, 3 year 20.43%
Growth rate% - EPS, 3 year 23.52%
Book value per share growth rate, 5 year 26.51%
Capital Spending growth rate, 5 year 32.48%
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR 20.44%
Displays analyst’s forecasts for key measures. The estimates can be expanded to see the spread of the calls. Full lines = reported, and dotted lines are forward estimates. Click a measure to add or remove it from the chart, sourced from Morningstar.

Financial forecast (DKK, millions except per share)

Actuals Estimates
2025 2026202720282029
Financial metrics can be plotted on the graph to see trends. Multiple metrics from multiple statements can be plotted against each other, sourced from Morningstar.

Financials (DKK, millions)

Period end: DEC 21DEC 22DEC 23DEC 24DEC 25
Fiscal year: 20212022202320242025
Period length: 12 months12 months12 months12 months12 months
Displays all company announcements released by the company to the exchange, sourced from Morningstar.

Announcements

Announcements are available for ASX-listed companies only.

Opinion

Action

Business Summary

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

image description

Relevant suggested news and content from the site

Back to top